ABMYVO Trademark
Trademark Overview
On Friday, November 10, 2023, a trademark application was filed for ABMYVO with the United States Patent and Trademark Office. The USPTO has given the ABMYVO trademark a serial number of 98264911. The federal status of this trademark filing is ABANDONED - EXPRESS AFTER PUB as of Tuesday, September 17, 2024. This trademark is owned by Reneo Pharmaceuticals, Inc.. The ABMYVO trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations for the treatment and prevention of mitochondrial diseases and disorders; pharmaceutical preparations for the treatment of genetic diseases and disorders; anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical products; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the pre...
General Information
| Serial Number | 98264911 |
| Word Mark | ABMYVO |
| Filing Date | Friday, November 10, 2023 |
| Status | 605 - ABANDONED - EXPRESS AFTER PUB |
| Status Date | Tuesday, September 17, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, July 23, 2024 |
Trademark Statements
| Goods and Services | Pharmaceutical preparations for the treatment and prevention of mitochondrial diseases and disorders; pharmaceutical preparations for the treatment of genetic diseases and disorders; anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical products; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of liver and kidney diseases and disorders; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical products for ophthalmological use; pharmaceutical products for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical products for the prevention and treatment of bone diseases; pharmaceutical products for the prevention and treatment of respiratory diseases and asthma; pharmaceutical preparations for the prevention and treatment of fibrosis |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 8 - Abandoned |
| Class Status Date | Tuesday, September 17, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Reneo Pharmaceuticals, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Irvine, CA 92612 |
| Party Name | Reneo Pharmaceuticals, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Irvine, CA 92612 |
Trademark Events
| Event Date | Event Description |
| Tuesday, November 14, 2023 | NEW APPLICATION ENTERED |
| Wednesday, December 13, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, June 18, 2024 | ASSIGNED TO EXAMINER |
| Thursday, June 20, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, July 3, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, July 23, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, July 23, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Thursday, August 15, 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Thursday, August 15, 2024 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Thursday, August 15, 2024 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Friday, August 16, 2024 | EXTENSION OF TIME TO OPPOSE RECEIVED |
| Monday, September 16, 2024 | TEAS EXPRESS ABANDONMENT RECEIVED |
| Tuesday, September 17, 2024 | ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION |
| Tuesday, September 17, 2024 | ABANDONMENT - AFTER PUBLICATION |
| Wednesday, November 20, 2024 | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED |
